Foster Wheeler AG (NASDAQ:FWLT) stock increased 2.34% to $18.34 after the company posted second-quarter net income of $30.9 million or $0.29 per share, as against $63.3 million or $0.52 per share reported a year ago. Operating revenues for the quarter declined to $943.03 million from last year's $1.18 billion. Analysts polled by Thomson Reuters expected the company to report earnings of $0.43 per share on revenues of $1.13 billion for the quarter.
Get Free Trend Analysis on FWLT
The Goodyear Tire & Rubber Company (NYSE:GT) stock surged 10.13% to $11.42 after the company reported second quarter net income of $86 million, or $0.33 per diluted share, as compared to $40 million, or $0.16 per diluted share, in the year ago period. Total Sales declined to $5.15 billion from $5.62 billion reported for the same quarter in the previous year. Analysts expected the company to report earnings of $45 per share on revenues of $5.74 billion for the quarter.
HCP, Inc. (NYSE:HCP) stock declined 0.06% to $47.10 after the company reported second quarter funds from operations, or FFO, of $293.62 million or $0.69 per share, as compared to $317.91 million or $0.78 per share in the same quarter last year. Net income for the quarter fell year-over-year to $201.47 million or $0.48 per share from $222.99 per share or $0.55 per share. Total revenues decreased to $464.44 million from $488.13 million in the prior year. Analysts expected the company to report earnings of $0.68 per share on revenues of $461.51 million for the quarter.
Get Free Trend Analysis on HCP
Louisiana-Pacific Corporation (NYSE:LPX) stock fell 6.99% to $10.24 after the company reported second-quarter net loss of $37.3 million or $0.27 per share, as compared to a loss of $35.5 million or $0.27 per share in the same quarter last year. Net sales rose to $427.8 million from $362.4 million in the prior year quarter. Analysts expected the company to report earnings of $0.05 per share on revenue estimate of $419.29 million for the quarter.
Pfizer Inc. (NYSE:PFE) stock increased 2.23% to $24.24 after the company announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).